Page 128 - 2019秋季手冊內頁-ebook測試

演講摘要 ABSTRACT From The 1st Generation to Develop The Next Generation of
Cancer Immune Cell Therapy
周德陽/中國醫藥大學附設醫院
Cancer immune cell therapies are promising for new hope of cancer therapy for a long time especially after chimeric antigen receptor T (CAR-T) treatment with or without immune checkpoint antibodies (PDL1-PD1, CTLA4) of immunotherapy. The 1st generation cancer immune cell treatment including dendritic cell (DC), cytokine induced T-cell (CIK), and gamma delta cell had some efficacy to some of individual cancer patient but still not predictable and satisfactory. CAR-T and bispecific T-cell engagers (BiTE) are successful to leukemia treatment, nearly curable, but they failed to the solid cancer. The tumor microenvironment is hostile and complicated. There are many inhibition immune checkpoint proteins, cytokines, myeloid cells, macrophages, regulatory T cells, ect. to interfere the immune cell approaching, and block their cytotoxic function even let them apoptosis.
The new next generation of cancer immune cell therapy is needed. There are two advanced platforms of cancer immune cell therapy, one is CAR and another is BiTE. The ideal the next generation of Immune cell therapy may be combined CAR and BiTE together on the robust gamma delta cell by nanobodies. It may be a promising cancer immune cell therapy to overcome the hardness and obstacle of tumor microenvironment.
129